3378 — Hanx Biopharmaceuticals (Wuhan) Cashflow Statement
0.000.00%
Last trade - 00:00- HK$3.59bn
- HK$3.10bn
Annual cashflow statement for Hanx Biopharmaceuticals (Wuhan), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -93.4 | -123 | -145 |
| Depreciation | |||
| Amortisation | |||
| Non-Cash Items | 47.4 | 26.2 | 20.6 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -7 | -13.8 | 15.6 |
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -52 | -105 | -102 |
| Capital Expenditures | -4.78 | -6.21 | -1.95 |
| Purchase of Fixed Assets | |||
| Purchase / Acquisition of Intangibles | |||
| Other Investing Cash Flow Items | 98.7 | 103 | 35.1 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | 94 | 96.6 | 33.1 |
| Financing Cash Flow Items | 0 | -2.55 | -34.8 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 90.2 | 6.49 | 525 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 132 | -0.786 | 453 |